Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:12
  • preuzimanja u poslednjih 30 dana:4

Sadržaj

članak: 9 od 24  
Back povratak na rezultate
2013, vol. 141, br. 9-10, str. 629-633
Genetički polimorfizmi paraoksonaze 1 i podložnost aterogenezi
aKliničko-bolnički centar Zvezdara, Beograd
bUniverzitet u Beogradu, Medicinski fakultet + Univerzitet u Beogradu, Medicinski fakultet, Institut za kardiovaskularne bolesti 'Dedinje'
cUniverzitet u Beogradu, Medicinski fakultet + Kliničko-bolnički centar Zvezdara, Beograd
dUniverzitet u Beogradu, Stomatološki fakultet

e-adresai.pejin@lab.kbczvezdara.co.rs
Projekat:
Genetička kontrola i molekularni mehanizmi u malignim, inflamatornim i razvojnim patologijama orofacijalne regije (MPNTR - 175075)

Ključne reči: paraoksonaza 1; genetički polimorfizmi; oksidativni stres; aterogeneza
Sažetak
Uvod. Paraoksonaza 1 (PON1) je multifunkcionalni enzim koji je vezan za lipoproteine visoke gustine (HDL). To je ćelijski antioksidans koji hidrolizuje oksidovane makromolekule, naročito oksidovane lipoproteine niske gustine (ox-LDL). Smatra se da povišeni oksidativni stres igra ključnu ulogu u inicijaciji i propagaciji ateroskleroze, pa su polimorfizmi u kodirajućem (Q192R i L55M) i promotorskom (C(-107)T) regionu gena pon1, koji su odgovorni za katalitičku efikasnost, aktivnost i nivo enzima, od velikog interesa kao potencijalni markeri osetljivosti na aterogenezu. Cilj rada. Cilj ove studije je bio da se ispita moguća povezanost varijanti gena pon1 i kliničkih manifestacija ateroskleroze i oksidativnog stresa. Metode rada. Analizirano je 60 bolesnika s angiografski dokumentovanim manifestacijama ateroskleroze i 100 zdravih ispitanika. Genomska DNK je izolovana iz ćelija periferne krvi, a genotipizacija je urađena primenom reakcije lančane polimeraze, posle koje je urađena analiza dužine restrikcionih fragmenata (tzv. PCR-RFLP analiza). Rezultati. Učestalosti alela i genotipova tri ispitivana polimorfizma nisu pokazale značajne razlike između ispitanika obolelih od ateroskleroze i zdravih osoba. Dobijeni rezultati ne ukazuju na povezanost analiziranih varijanti gena pon1 i oksidativnog stresa i aterogeneze. Zaključak. Ovi polimorfizmi se ne mogu smatrati faktorima rizika za razvoj ateroskleroze u srpskoj populaciji. Potrebna je studija sa većim brojem ispitanika, kako bi se utvrdio mogući doprinos varijanti gena pon1 na nastanak kardiovaskularnih oboljenja u čijoj osnovi je ateroskleroza.
Reference
*** (2011) World Health Statistics - 2011. Geneve: World Health Organization
Adkins, S., Gan, K.N., Mody, M., la Du, B.N. (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet, 53: 598-608
Antikainen, M., Murtomäki, S., Syvänne, M., Pahlman, R., Tahvanainen, E., Jauhiainen, M., Frick, M.H., Ehnholm, C. (1996) The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. Journal of Clinical Investigation, 98(4): 883-885
Aviram, M., Kaplan, M., Rosenblat, M., Fuhrman, B. (2005) Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handbook of Experimental Pharmacology, 170: 263-300
Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., Rosenblat, M. (2000) Human Serum Paraoxonases (PON1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic Lesions : PON1 Esterase and Peroxidase-Like Activities. Circulation, 101(21): 2510-2517
Bayrak, A., Bayrak, T., Tokgözoglu, L.S., Volkan-Salanci, B., Deniz, A., Yavuz, B., Alikasifoglu, M., Demirpençe, E. (2012) Serum PON-1 Activity but not Q192R Polymorphism is Related to the Extent of Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 19(4): 376-384
Brophy, V.H., Jampsa, R.L., Clendenning, J.B., McKinstry, L.A., Jarvik, G.P., Furlong, C.E. (2001) Effects of 5′ Regulatory-Region Polymorphisms on Paraoxonase-Gene (PON1) Expression. American Journal of Human Genetics, 68(6): 1428-1436
Clarimon, J., Eerola, J., Hellström, O., Tienari, P.J., Singleton, A. (2004) Paraoxonase 1 (PON1) gene polymorphisms and Parkinson’s disease in a Finnish population. Neuroscience Letters, 367(2): 168-170
Costa, L.G., Cole, T.B., Furlong, C.E. (2005) Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta bio-medica, 76 Suppl 2: 50-7
Đurić, G., Svetel, M., Illarioškin, N.S., Dragađević, N., Gavrilović, J., Kostić, V.S. (2007) Polimorfizmi gena citohrom oksidaze P450 2D6 (CYP2D6), paraoksonaze 1 (PON1) i apolipoproteina (APOE) kao faktori rizika od razvoja Parkinsonove bolesti. Vojnosanitetski pregled, vol. 64, br. 1, str. 25-30
Flekac, M., Skrha, J., Zídková, K., Lacinová, Z., Hilgertová, J. (2008) Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiological research, 57(5): 717-26
Futterman, L.G., Lemberg, L. (1998) Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. American journal of critical care, 7(3): 240-4
Gaidukov, L., Rosenblat, M., Aviram, M., Tawfik, D.S. (2006) The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. Journal of Lipid Research, 47(11): 2492-2502
Grdić, M., Barišić, K., Rumora, L., Salamunić, I., Tadijanović, M., Žanić-Grubišić, T., Pšikalova, R., Fleger-Meštrić, Z., Juretić, D. (2008) Genetic frequencies of paraoxonase 1: Gene polymorphisms in croatian population. Croat Chem Acta, 81, str. 105-111
Humbert, R., Adler, D.A., Disteche, C.M., Hassett, C., Omiecinski, C.J., Furlong, C.E. (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics, 3(1): 73-76
James, R.W., Leviev, I., Ruiz, J., Passa, P., Froguel, P., Garin, M.C. (2000) Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes, 49(8): 1390-1393
Leviev, I., Deakin, S., James, R.W. (2001) Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. Journal of lipid research, 42(4): 528-35
Leviev, I., James, R.W. (2000) Promoter Polymorphisms of Human Paraoxonase PON1 Gene and Serum Paraoxonase Activities and Concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology, 20(2): 516-521
Mackness, M.I., Arrol, S., Durrington, P.N. (1991) Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letters, 286(1-2): 152-154
Navab, M., Hama-Levy, S., van Lenten, B.J., Fonarow, G.C., Cardinez, C.J., Castellani, L.W., Brennan, M.L., Lusis, A.J., Fogelman, A.M., la Du, B.N. (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. Journal of Clinical Investigation, 99(8): 2005-2019
Parra, S., Alonso-Villaverde, C., Coll, B., Ferré, N., Marsillach, J., Aragonès, G., Mackness, M., Mackness, B., Masana, L., Joven, J., Camps, J. (2007) Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis, 194(1): 175-181
Primo-Parmo, S.L., Sorenson, R.C., Teiber, J., la Du, B.N. (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 33(3): 498-507
Rosenblat, M., Karry, R., Aviram, M. (2006) Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis, 187(1): 74-81
Sardo, M.A., Campo, S., Bonaiuto, M., Bonaiuto, A., Saitta, C., Trimarchi, G., Castaldo, M., Bitto, A., Cinquegrani, M., Saitta, A. (2005) Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Current Medical Research and Opinion, 21(5): 777-784
Taşkiran, P., Cam, S.F., Sekuri, C., Tüzün, N., Alioğlu, E., Altintaş, N., Berdeli, A. (2009) The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Türk Kardiyoloji Derneği arşivi, 37(7): 473-8
Wheeler, J.G., Keavney, B.D., Watkins, H., Collins, R., Danesh, J. (2004) Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies. Lancet, 363(9410): 689-695
 

O članku

jezik rada: engleski
vrsta rada: originalan članak
DOI: 10.2298/SARH1310629G
objavljen u SCIndeksu: 13.11.2013.